Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

44
Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007

Transcript of Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

Page 1: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

Safety of Pentacel

Karen Farizo, M.D.

CBER

VRBPAC

January 25, 2007

Page 2: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

2

Overview of Presentation

• Pivotal Clinical Studies

• Supportive Post-Marketing Safety Data

Page 3: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

3

Pivotal Studies

Design Overall Safety Database

Safety Monitoring Subject Disposition

Subject Demographics

Page 4: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

4

Study 494-01

Country/Dates

Pentacel and Control Vaccines Schedule

Concomitant Vaccines

Pentacel N

Control N

U.S./12/1999-4/2002

Pentacel: 2, 4, 6, 15 m

HCPDT* + POLIOVAX + ActHIB: 2, 4, 6, 15 m

Prevnar: 2, 4, 6 m (~80%)

RECOMBIVAX HB: 2, 6 m

2506 1032

*HCPDT = DTaP component of Pentacel (not U.S. licensed)

Page 5: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

5

Study P3T06

Country/Dates

Pentacel and Control Vaccines Schedule

Concomitant Vaccines

Pentacel N

Control N

U.S./5/2001-1/2004

Pentacel: 2, 4, 6, 15-16 m

DAPTACEL + ActHIB:2, 4, 6, 15-16 m; IPOL: 2, 4, 6 m

Prevnar: 2, 4, 6 m

RECOMBIVAX HB: 2, 6 m

485 Doses 1-3: 1454

Dose 4: 418

Page 6: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

6

Studies 494-03 and 5A9908

Study/Country/Dates

Pentacel Schedule Concomitant Vaccines

Pentacel N

494-03/U.S./7/2000-12/2002

2, 4, 6, 15-16 m

•Prevnar: 2, 4, 6 m •RECOMBIVAX HB: 2, 4, 6 m or 2, 6 m. •Prevnar, MMRII, VARIVAX:

with 4th dose of Pentacel or staggered

1207

5A9908/Canada/8/2000-10/2001

15, 16, 17 or 18 m

none 1782

Page 7: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

7

Pivotal Studies: Overall Pentacel Safety Database

• A total of 5,980 subjects received at least one dose of Pentacel.

• 4,198 subjects were from studies of four consecutive doses of Pentacel.

• 1,782 subjects were from a study of the fourth dose only.

• Overall, 17,021 doses of Pentacel were administered.

Page 8: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

8

Pivotal Studies: Safety Monitoring

Safety monitoring included:

• Observation for 30 minutes at study site

• Solicited local reactions and systemic events recorded daily on diary cards Days 0-7

• Serious adverse events monitored through 60 days (3 studies) or 180 days (Study P3T06) following the last dose of study vaccines

• Periodic phone calls to inquire about adverse events (Day 2-4, 8, 30, 60 after each dose; also Day 180 post-Dose 4 in Study P3T06)

Page 9: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

9

Pivotal Studies: Completion of Safety Follow-up

494-01 494-03 P3T06 5A9908

Pentacel Control Pentacel Pentacel Control Pentacel

Participation* (N) 2506 1032 1207 484 1455 1782

60 day follow-up post-dose 3 (%) 90 85 88 93 93 n/a

60 or 180 day follow-up post-dose 4** (%)

75 68 79 86 84 >99

n/a indicates not applicable*participation by randomized group for Studies 494-01 and P3T06**60 days in Studies 494-01, 494-03 and 5A9908; 180 days in Study P3T06

Page 10: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

10

Pivotal Studies: Demographics of Pentacel Safety Population

Studies 494-01, 494-03, P3T06

N = 4198

Study 5A9908

N = 1782

Mean age at 1st dose (mo.) 2.1 n/a

% Male 49.8 48.3

Race/Ethnicity % Caucasian Black Hispanic Asian East Indian Native Indian Other

61.1 9.8

15.0 4.3 n/an/a9.7

86.01.90.84.32.00.54.5

n/a indicates not applicable.East Indian and Native Indian categories applied only to Study 5A9908.

Page 11: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

11

Pivotal Studies

Serious Adverse Events

Page 12: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

12

Pivotal Studies: Percent of Subjects with a Serious Adverse Event within 30 Days following Doses 1-3 of Study Vaccines

494-01 494-03 P3T06

HCPDT + POLIOVAX + ActHIBN=1032

PentacelN=2506

PentacelN=1207

DAPTACEL + IPOL + ActHIBN=1455

PentacelN=484

1.1 0.9 2.1 3.4 3.9

Page 13: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

13

Pivotal Studies: Percent of Subjects with a Serious Adverse Event within 30 Days following Dose 4 of Study Vaccines

494-01 494-03 P3T06 5A9908

HCPDT + POLIOVAX + ActHIBN=739

PentacelN=1862

PentacelN=958

DAPTACEL + ActHIB

N=418PentacelN=431

PentacelN=1782

0.3 0.3 0.8 1.0 1.2 1.1

Page 14: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

14

Pivotal Studies: Most Frequent* Serious Adverse Events within 30 Days following Doses 1-3, Percent of Subjects

494-01 494-03 P3T06

ControlN=1032

PentacelN=2506

PentacelN=1207

ControlN=1455

PentacelN=484

Bronchiolitis 0.6 0.2 0.7 1.9 0.8

Dehydration 0.0 0.1 0.2 0.1 0.6

Pneumonia** 0.0 0.1 0.2 0.1 0.4

Gastroenteritis** 0.0 <0.1 0.1 0.2 0.4

Otitis media** 0.0 0.1 0.2 0.0 0.0

Bronchospasm** 0.1 0.1 0.1 0.0 0.0

Gastroenteritis rotavirus 0.0 0.1 0.1 0.0 0.2

GE reflux 0.0 <0.1 0.2 0.1 0.0

Otitis media chronic** 0.0 0.0 0.0 0.1 0.4*occurring in at least 4 subjects overall**not otherwise specifiedControl: 494-01 HCPDT, POLIOVAX, ActHIB; P3T06 DAPTACEL, IPOL, ActHIB

Page 15: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

15

Pivotal Studies: Most Frequent* Serious Adverse Events within 30 Days following Dose 4, Percent of Subjects

494-01 494-03 P3T06 5A9908

ControlN=739

PentacelN=1862

PentacelN=958

ControlN=418

PentacelN=431

PentacelN=1782

Dehydration 0.0 0.0 0.1 0.5 0.0 0.2

Gastro-enteritis** 0.0 0.0 0.0 0.2 0.2 0.2

Asthma** 0.0 0.1 0.0 0.0 0.2 0.1

Pneumonia** 0.0 0.1 0.0 0.0 0.0 0.2

*occurring in at least 4 subjects overall**not otherwise specifiedControl: HCPDT + POLIOVAX + ActHIB (494-01); DAPTACEL + ActHIB (P3T06)

Page 16: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

16

Pivotal Studies: Serious Adverse Events-- Deaths

Vaccine Group*

Age (mo.) at death

Last dose

Days since

last doseCause of death

Pentacel 15 4 8 Asphyxia due to suffocation

Pentacel 2 1 23 Head trauma

Pentacel 4 1 52 SIDS

Pentacel 15 3 256 Neuroblastoma

DAPTACEL + IPOL + ActHIB

13 3 222 Aspiration; metastatic ependymoma

*Pentacel N=5980; DAPTACEL N=1454; HCPDT N=1032

Page 17: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

17

Pivotal Studies: Serious Adverse Events-- Encephalopathy

• Case 1– hypoxic ischemic encephalopathy• secondary to cardiac arrest following surgical repair of

congenital heart defects 30 days after the first dose of Pentacel

• Case 2– congenital encephalopathy• 7-week old infant developed head lag, loss of visual

following, and tremors 8 days after the first dose of Pentacel

• Several café au lait spots and subtle left hemiparesis on exam

• MRI: Left frontal horn enlargement; left frontal atrophy

Page 18: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

18

Pivotal Studies

Seizures

Page 19: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

19

Pivotal Studies: Use of Antipyretics within 3 Days Post-Vaccination

• For Doses 1, 2, and 3, approximately ~40-50% of subjects reported use of an antipyretic within 3 days following Pentacel or Control vaccines.

• For Dose 4, approximately 33% of subjects reported use of an antipyretic within 3 days following Pentacel or Control vaccines.

• In the controlled studies, use of antipyretics was similar between vaccine groups.

Page 20: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

20

Pivotal Studies: Seizures within 7 days Post-Vaccination, Number (%) of Subjects

HCPDT + POLIOVAX +

ActHIBDoses 1-3: N=1032

Dose 4: N=739

DAPTACEL + IPOL + ActHIB*

Doses 1-3: N=1455

Dose 4: N=418

Pooled PentacelDoses 1-3:

N=4197Dose 4: N=5033

Febrile Doses 1-3 Dose 4

0 (0.0) 2 (0.3)

0 (0.0)0 (0.0)

0 (0.0)2 (<0.1)

Afebrile Doses 1-3 Dose 4

1 (0.1) 0 (0.0)

1 (0.1) 0 (0.0)

1 (<0.1)0 (0.0)

Possible Doses 1-3 Dose 4

0 (0.0)0 (0.0)

0 (0.0)0 (0.0)

1 (<0.1) 0 (0.0)

*Dose 4: DAPTACEL + ActHIB

Page 21: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

21

Pivotal Studies: Febrile Seizures* within 7 Days Post-Vaccination

Study group

Age

(mo.)

Last Dose

Interval (days)** Additional Clinical Information

HCPDT 15 4 6 URI; recovered w/o sequelae

HCPDT 17 4 7 Viral illness; recovered w/o sequelae

Pentacel 15 4 2 Pharyngitis; recovered w/o sequelae

Pentacel 17 4 4 URI; recovered w/o sequelae

Pentacel 6 3 0 Possible seizure; fever noted same day; recovered w/o sequelae

*includes one possible seizure **Interval since last dose

Page 22: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

22

Pivotal Studies: Afebrile Seizures within 7 Days Post-Vaccination

Study group

Age

(mo.)

Last Dose

Interval*

(days) Additional Clinical Information

HCPDT 4 2 0 •Migraine variant seizure activity

•Unspecified head injury 26 d earlier

•2 siblings with acute hemiparesis associated with unilateral seizure

•Follow-up 2.5 yrs after discontinuation from the study indicated continued seizures

Pentacel 2 1 6 •Recovered w/o sequelae

•Completed study w/o further seizures

DAPTACEL 1 1 0 •15 sec of twitching and staring; 5 sec of apnea

•Recovered w/o sequelae*Interval since last dose

Page 23: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

23

Pivotal Studies

Hypotonic Hyporesponsive Episodes (HHEs)

Page 24: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

24

Pivotal Studies: Hypotonic Hyporesponsive Episodes Definition

An event of sudden onset:

• occurring within 48 hours of vaccination

• with duration ranging from 1 minute to 48 hours

• involving: 1) limpness or hypotonia, 2) hyporesponsiveness, and 3) pallor or cyanosis or failure to observe or to recall skin coloration

• without known cause (e.g., postictal) or urticaria

Page 25: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

25

Pivotal Studies: Monitoring for Hypotonic Hyporesponsive Episodes

• Studies 494-01, 494-03 and 5A9908: During post-vaccination phone calls, parents were asked about fainting or change in mental status.

• Study P3T06: The diary card included specific questions pertaining to symptoms of HHEs.

Page 26: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

26

Pivotal Studies: Hypotonic Hyporesponsive Episodes

• There were no reports of HHE following:

Pentacel (N = 5,980 subjects; 17,021 doses), HCPDT (N = 1,032 subjects; 3,616 doses), or DAPTACEL (N = 1,454 subjects; 4,648

doses).

• One subject who received DAPTACEL reported an event that met the criteria for HHE except that it occurred 16 days post-vaccination.

• Historically, in the Sweden II Efficacy Trial, the rate of HHE following HCPDT was 14/10,000 subjects or 0.47/1,000 doses.

• Historically, in the Sweden I Efficacy Trial, there was one report of HHE among 2,587 subjects (7,703 doses) who received DAPTACEL.

Page 27: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

27

Pivotal Studies

Solicited Systemic and

Local Adverse Events

Page 28: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

28

Controlled Pivotal Studies: Routes of Temperature Measurement

• Post-doses 1-3 of Pentacel or Control vaccines: • Parents were instructed to measure temperature rectally.

• In both studies, ~45% of temperature measurements were axillary and ~50% were rectal.

• Post-dose 4 of Pentacel or Control vaccines: • Parents were instructed to measure temperature rectally

in one study and axillary in one study.

• In both studies, ~60-70% of temperature measurements were axillary and ~25-30% were rectal.

• Routes of temperature measurement were similar between the Pentacel and Control groups.

Page 29: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

29

Study P3T06: Percent of Subjects with Fever within 3 Days Post-Vaccination

Dose 1 Dose 2 Dose 3 Dose 4

Pentacel (N=389-466) ≥38.0°C >38.5°C >39.5°C

5.81.30.4

10.92.40.0

16.34.40.7

13.45.10.3

Control* (Doses 1-3: N=1301-1390; Dose 4: N=379) ≥38.0°C >38.5°C >39.5°C

9.31.60.1

16.14.30.4

15.85.10.3

8.73.20.8

*Control = DAPTACEL + IPOL + ActHIB for doses 1-3; DAPTACEL + ActHIB for dose 4

Page 30: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

30

Study 494-01: Percent of Subjects with Fever within 3 Days Post-Vaccination

Dose 1 Dose 2 Dose 3 Dose 4

Pentacel (N=1630-2296)

≥38.0°C

>38.5°C

>39.5°C

8.1

1.5

0.3

14.3

3.5

0.2

19.3

6.1

0.8

10.7

2.6

0.7

Control* (N=634-920)

≥38.0°C

>38.5°C

>39.5°C

13.8

2.3

0.1

15.7

4.9

0.6

20.6

4.6

0.7

13.1

3.9

0.5*Control = HCPDT + POLIOVAX + ActHIB

Page 31: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

31

Study 494-01: Percent of Subjects with Fever within 3 Days following Pentacel, by Route of Measurement

Dose 1 Dose 2 Dose 3 Dose 4

Rectal N=1241 N=1184 N=1119 N=451

>38.0°C>38.5°C>39.5°C

11.61.60.3

20.84.50.2

25.78.20.9

23.13.80.7

Axillary N=1156 N=980 N=891 N=1193

>38.0°C>38.5°C>39.5°C

3.61.20.3

5.71.90.3

9.53.10.6

5.92.10.7

N = number of subjects with a recorded temperature by specified route. At each dose, subjects who switched route during the 0-3 day period (~5%) are included in both categories.

Page 32: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

32

Pivotal Studies: Medically Attended Fever

• Not specifically solicited

• Limitations in ability to capture medically attended fever from the database

• Outpatient and Emergency Department cases may be missed if not considered a serious adverse event.

• Cases in which the reported diagnosis did not include “fever” or “pyrexia” would be missed.

Page 33: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

33

Study P3T06: Percent of Subjects with Selected Solicited Systemic Events within 3 Days Post-Vaccination

PentacelN=398-467

DAPTACEL+ IPOL* + ActHIBDoses 1-3: N=1312-1406

Dose 4: N=381

Dose 1 2 3 4 1 2 3 4

Less ActiveAny Severe**

45.82.1

32.70.7

32.50.2

24.12.5

51.11.2

37.41.4

33.20.6

24.10.3

Inconsolable Crying Any >3 hours

59.31.9

49.80.9

47.31.1

35.92.3

58.52.2

51.43.4

47.91.4

36.21.8

Fussiness Any >3 hours

76.94.3

71.24.0

68.05.0

53.55.3

75.85.6

70.75.5

67.14.3

53.84.5

*DAPTACEL + ActHIB for Dose 4**Disabling, not interested in usual activity

Page 34: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

34

Study P3T06: Percent of Subjects with Solicited Local Events within 3 Days Post-Vaccination

Pentacel Injection Site N=392-467

DAPTACEL Injection SiteDoses 1-3: N=1311-1404

Dose 4: N= 378-380

Dose 1 2 3 4 1 2 3 4

Redness>5 mm >25 mm>50 mm

7.12.80.6

8.41.80.2

8.71.80.0

17.39.22.3

6.2 1.00.4

7.10.60.1

9.6 1.90.0

16.47.92.4

Swelling >5 mm >25 mm>50 mm

7.53.00.9

7.32.00.0

5.01.60.0

9.73.80.8

4.01.60.4

4.00.70.1

6.51.10.1

10.34.01.3

TendernessAny Severe*

47.55.4

39.21.6

42.71.4

56.13.3

48.84.1

38.22.3

40.91.7

51.12.4

*Cries when arm or leg is moved

Page 35: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

35

PentacelPost-Marketing Safety

Experience

Page 36: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

36

Pentacel Post-Marketing Safety Experience

• Pentacel was first registered in Canada in 1997 and is currently licensed in 8 countries.

• Since 1997-1998, Pentacel (at 2, 4, 6 and 18 months of age) and DTaP-IPV (Sanofi Pasteur Limited) (at 4-6 years of age) have been used exclusively in Canada to prevent pertussis, polio, and invasive Hib disease through early childhood.

• Between May 1997 and April 2006, ~13.5 million doses of Pentacel were distributed outside the U.S., 92% of them in Canada.

• Annual birth cohort in Canada in 2001-2002 was ~330,000.

Page 37: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

37

Post-Marketing Spontaneous Reports of Adverse Events following Pentacel: 5/1/97-4/30/06 (~13.5 million doses distributed)

• Sanofi Pasteur received 288 adverse event reports from health care professionals and health authorities, consumers, and literature sources.

• The 5 most frequently reported events were: • Injection site reaction

• Pyrexia

• Crying

• Injection site inflammation

• Irritability

Page 38: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

38

Post-Marketing Reports of SIDS and Other Deaths without Known Cause following Pentacel, 5/1/97-4/30/06 (~13.5 million doses distributed)

Ageat Death

Interval Since Vx

Co-administeredVaccines

Reporting Term

2 m 1 d -- SIDS

2 m 2 d -- SIDS

2 m 7 d Prevnar SIDS

2 m 8 d Prevnar SIDS

2 m 13 d -- SIDS

4 m 24 hr Meningococcal C Sudden death

2 m 8 d -- Sudden death

36 m 11 d Hepatitis B, MMR, Meningococcal

Sudden death

19 m 25 d -- Death-- indicates none reported

Page 39: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

39

Post-Marketing Reports of Deaths with Identified Cause following Pentacel, 5/1/97-4/30/06 (~13.5 million doses distributed)

Ageat Death

Interval Since Vx

Co-administeredvaccines

Events/Cause of Death

2 m 9 hr -- Group B Streptococcal sepsis (reported as ongoing since birth)

2 m 3 d -- Unspecified congenital anomaly; cardiac myopathy

5 m 3 m -- Hib meningitis/pneumonia(post-Dose 1)

3 m 30 d -- Hib meningitis (post-Dose 1)

20 m n/a -- Convulsionsn/a: data not available-- indicates none reported

Page 40: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

40

Post-Marketing Cases of Encephalopathy following Pentacel, 5/1/97-4/30/06 (~13.5 million doses distributed)

AgeDays

Since Vx Clinical Information

18 m 1 •Fever, cough, coryza, status epilepticus •Cerebral edema on CT; Influenza A from NP aspirate

4 m 5 •Fever, vomiting, bloody diarrhea, ↑ liver enzymes, status epilepticus, coma*•Cerebral edema, laminar necrosis, cortical bleeding•CSF nl; no organism identified (respiratory/stool/CSF)

2 m 7 •Fever, abnormal crying, cough, apnea, seizures•Cranial CT and CSF normal•Influenza A from NP aspirate

18 m 10 •Atypical Kawasaki syndrome with acute encephalopathy**•Also received MMR

4 m 24 •Convulsions, infantile spasms, hepatosplenomegaly, pneumonia, developmental delay

*Case coded as convulsions **Identified in a post-marketing survey conducted in Canada

Page 41: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

41

Immunization Monitoring Program, Active (IMPACT)

• IMPACT is a nationwide Canadian hospital-based program that conducts active surveillance for selected post-vaccination adverse events.

• Participating hospitals• encompass ~90% of Canada’s tertiary care pediatric beds

• serve an immediate population base of 3 million children (~1/2 of Canada’s population <15 yrs of age)

• receive referrals from outside immediate catchment areas

• All admissions for acute neurological illness are screened for recent immunization.

Page 42: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

42

IMPACT: Encephalopathy, 1993-2002

• Encephalopathy or encephalitis within 7 days after pertussis vaccination identified at IMPACT centers:

• 3 after whole-cell pertussis

• 4 after acellular pertussis (3 Pentacel; 1 DTaP-IPV).

• One case had direct evidence of HSV brain infection. Other cases had plausible alternative causes.

• Considering estimated doses of pertussis vaccines administered to Canadian children (6 million whole-cell and 7 million acellular) and the size of the IMPACT catchment population, the estimated risk, if any, of encephalopathy or encephalitis attributable to vaccination:

• <1 per 3 million doses of whole-cell pertussis vaccine

• <1 per 3.5 million doses of acellular pertussis vaccine.

(Moore DL et al. Pediatr Infect Dis J 2004;23:568-571)

Page 43: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

43

IMPACT: Febrile Seizures and Hypotonic Hyporesponsive Episodes

• Active surveillance for seizures and HHEs resulting in hospitalization and HHEs seen in emergency departments

• Using Poisson regression models, average monthly admissions for seizures and reports of HHEs compared between 1995-1996 (whole cell DTP period) and 1998-2001 (Pentacel period)

• Between the whole cell DTP period and the Pentacel period:• Hospitalizations for febrile seizures within 72 hours after

pertussis vaccine decreased 79%

• Reports of HHEs within 48 hours after pertussis vaccine decreased 60%

• Hospitalizations for febrile seizures within 5-30 days after MMR did not change significantly.

(LeSaux N, et al. Pediatrics. 2003;112:e348-353)

Page 44: Safety of Pentacel Karen Farizo, M.D. CBER VRBPAC January 25, 2007.

44

Summary– Pentacel Safety Database

• The safety of Pentacel was evaluated in a total of 5,980 subjects from four pivotal clinical studies.

• 4,198 subjects were from studies of four consecutive doses.

• 1,782 subjects were from a study of the fourth dose only.

• In two studies, Pentacel was compared to separately administered Control vaccines: HCPDT, POLIOVAX and ActHIB in one study, and DAPTACEL, IPOL and ActHIB in the other.

• Supportive post-marketing safety data reflect distribution of ~13.5 million doses of Pentacel over a 9-year period, primarily in Canada.